South Korea CAR-NK Cell Therapy Market by Cell Source, Target Antigen, Indication, Route of Administration, End User and Sales Forecast - Trends and Forecast Till 2035

SOUTH KOREA CAR-NK CELL THERAPY MARKET: OVERVIEW

South Korea CAR-NK cell therapy market size is estimated to be USD 0.02 billion in the current year and is projected to reach USD 0.35 billion by 2035, at a compound annual growth rate of 37.4% during the forecast period, till 2035.

South Korea CAR-NK Cell Therapy Market: Growth and Trends

The South Korea CAR-NK cell therapy market is witnessing an upward trajectory, driven by rising cancer incidence, government support for advanced regenerative biologics, and growing domestic capabilities in cell and gene therapy manufacturing. CAR-NK therapy combines the tumor-targeting precision of chimeric antigen receptors with the innate cytotoxic activity of natural killer (NK) cells, offering a potentially safer, allogeneic, off-the-shelf alternative to autologous CAR-T therapy. With domestic innovators such as GC Cell and NKGen Biotech, an active licensing environment, and a streamlined regulatory pathway under the Advanced Regenerative Bio Act, South Korea is emerging as a regional hub for CAR-NK research and clinical development, with commercialization potential through 2035.

The sector is also benefiting from advances in scalable NK-cell manufacturing. CAR-NK products derived from cord blood, peripheral blood, induced pluripotent stem cells (iPSCs), and established NK cell lines are gaining attention because of their potential for allogeneic, off-the-shelf production and lower risks of cytokine release syndrome, neurotoxicity, and graft-versus-host disease compared with CAR-T therapy. Domestic companies are strengthening this ecosystem through pipeline development and partnerships, including Daewoong Pharmaceutical’s collaboration with UCI Therapeutics and GC Cell’s 2025 licensing agreement with DAAN Biotherapeutics. Meanwhile, NKGen Biotech continues to advance engineered NK-cell platforms targeting both hematological malignancies and solid tumors.

Government support and strong biomanufacturing and clinical infrastructure further reinforce South Korea’s position. Expedited regulatory pathways, R&D incentives, and investments in cell and gene therapy manufacturing are complemented by leading biomanufacturing companies such as Samsung Biologics and SK bioscience, as well as major academic and clinical centers. Together, these factors create a favorable environment for advancing CAR-NK therapies from research and clinical development toward commercialization.

Market Challenges: Critical Barriers Impeding Progress

Despite a promising trajectory, the South Korea CAR-NK cell therapy market faces several structural challenges. Limited in-vivo persistence and expansion of infused NK cells remain an active area of research, as durability of response continues to trail that observed with some CAR-T therapies in hematological indications. Manufacturing complexity, particularly for iPSC-derived and genetically engineered NK cell products, requires specialized infrastructure, stringent quality control, and skilled talent. These capabilities remain relatively limited even within South Korea’s advanced biomanufacturing ecosystem.

Reimbursement uncertainty is a further consideration, as national health insurance frameworks continue to evolve to accommodate high-cost, single-administration cell and gene therapies. Notably, most CAR-NK candidates remain in pre-clinical or early clinical development. Therefore, developers must also navigate the inherent risks of small-scale trials, limited long-term safety and efficacy data, and competitive pressure from more clinically mature CAR-T and monoclonal antibody therapies. Addressing these barriers through continued clinical validation, manufacturing innovation, and proactive engagement with regulators and payers will be essential to unlocking the market's full commercial potential.

South Korea CAR-NK Cell Therapy Market: Key Insights

This report examines the current state of South Korea's CAR-NK cell therapy market and identifies the trends most likely to shape its evolution through 2035. Selected findings include:

• Domestic pharmaceutical players and specialized biotechs are increasingly co-developing CAR-NK candidates through licensing and collaboration agreements rather than pursuing standalone in-house pipelines, reflecting a capital-efficient path to market entry.
• Hematological malignancies currently represent the primary focus of early-stage CAR-NK development in South Korea, while a growing share of newer candidates are being engineered to target solid tumor antigens, reflecting the broader industry shift beyond blood cancers.
• Allogeneic, cord blood, peripheral blood, and iPSC-derived NK cell platforms are gaining relative traction over autologous approaches, owing to their scalability and off-the-shelf manufacturing advantages.
• Hospitals and specialized cancer research institutes, led by academic medical centers in the Seoul metropolitan area, are expected to remain the dominant end users of CAR-NK therapies given the infrastructure and expertise required for cell therapy administration and patient monitoring.
• South Korea's contract development and manufacturing (CDMO) capacity is emerging as a strategic asset, positioning domestic manufacturers to support both local developers and international CAR-NK sponsors seeking Asia-Pacific production capability.
• Partnership activity between South Korean biotechs and global cell therapy innovators is increasing, with licensing deals structured around upfront payments, development milestones, and shared commercialization rights.
• Regulatory support through the Advanced Regenerative Bio Act is shortening development timelines relative to prior years, encouraging earlier-stage trial initiation in South Korea for both domestic and international CAR-NK programs.
• Given the rising prevalence of cancer, an expanding clinical pipeline, and continued policy support for regenerative medicine, the South Korea CAR-NK cell therapy market is well-positioned for sustained growth over the coming decade.

South Korea CAR-NK Cell Therapy Market: Segments

The market sizing and opportunity analysis featured in this report has been segmented across the following parameters:

By Cell Source

• Cord Blood-derived NK Cells
• Peripheral Blood-derived NK Cells
• iPSC-derived NK Cells
• NK Cell Lines

By Target Antigen

• CD19
• CD22
• BCMA
• GPC3
• CD33
• Other Tumor-associated Antigens

By Indication

• Hematological Malignancies
• Solid Tumors

By Route of Administration

• Intravenous
• Locoregional / Intratumoral

By End User

• Hospitals
• Cancer Research Institutes
• Ambulatory Surgical Centers

South Korea CAR-NK Cell Therapy Market: Key Segment Insights

Allogeneic NK Cell Platforms Hold High Share

Based on our market assessment, allogeneic NK cell platforms sourced from cord blood are expected to gain share relative to autologous approaches over the forecast period. This shift is being driven by the scalability of donor-independent manufacturing, the potential for lower per-dose production costs at commercial volumes, and shorter vein-to-vein turnaround time, all of which align with the efficiency priorities of South Korea's centralized healthcare system.

Hematological Malignancies Lead, Solid Tumors Emerge as the Next Frontier

Hematological malignancies currently hold the highest market share, consistent with global trends in engineered cell therapy, given more clearly defined tumor antigens and easier immune cell access. However, solid tumor-targeted candidates are expected to expand at a faster relative CAGR over the forecast period as developers apply lessons learned from hematological programs to more complex tumor microenvironments.

Hospitals and Academic Cancer Centers Anchor Demand

Hospitals and specialized cancer research institutes, concentrated around leading academic medical centers, are expected to account for the majority of CAR-NK therapy administration in South Korea. This reflects the advanced infrastructure, cell processing capability, and multidisciplinary oncology teams required to safely deliver and monitor engineered cell therapies.

Example Players In The South Korea CAR-NK Cell Therapy Market

• Boryung
• Curocell
• DAAN Biotherapeutics
• Daewoong Pharmaceutical
• GC Cell
• NKGen Biotech (formerly NKMax)
• National Cancer Center, South Korea
• Samsung Biologics (manufacturing partner)
• UCI Therapeutics

SOUTH KOREA CAR-NK CELL THERAPY MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: An in-depth analysis of the South Korea CAR-NK cell therapy market focused on key segments, including cell source, target antigen, indication, route of administration, end user, and sales forecast.
• Therapies Landscape: A detailed assessment of the CAR-NK therapy pipeline relevant to South Korea, covering stage of development, target antigen, cell source, route of administration, and headquarters location.
• Company Profiles: In-depth profiles of prominent players engaged in the South Korea CAR-NK ecosystem, featuring year of establishment, headquarters, portfolio, and key initiatives.
• Clinical Trial Analysis: An analysis of completed, ongoing, and planned clinical trials relevant to CAR-NK cell therapy in South Korea, based on trial phase, status, sponsor type, and patient population.
• Recent Developments: A review of recent partnerships, licensing agreements, funding rounds, and strategic collaborations shaping the South Korea CAR-NK cell therapy landscape.
• Porter's Five Forces Analysis: A qualitative assessment of competitive dynamics, including threat of new entrants, bargaining power of buyers and suppliers, threat of substitutes, and rivalry among existing players.
• Market Impact Analysis: An evaluation of the drivers, restraints, opportunities, and challenges shaping market growth through 2035.

KEY QUESTIONS ANSWERED IN THIS REPORT

• What is the current and projected size of the South Korea CAR-NK cell therapy market through 2035?
• Which companies are leading CAR-NK cell therapy development and commercialization in South Korea?
• What are the key trends shaping CAR-NK cell therapy adoption in South Korea?
• How is the South Korea CAR-NK cell therapy market segmented by cell source, target antigen, indication, and end user?
• What regulatory and reimbursement factors are influencing market growth?
• What are the primary challenges facing CAR-NK cell therapy developers in South Korea?
• Which recent partnerships, licensing deals, and funding rounds are shaping the competitive landscape?
• How does the South Korea market compare with broader Asia-Pacific CAR-NK cell therapy trends?

REASONS TO BUY THIS REPORT

• Provides a comprehensive, data-backed analysis of the South Korea CAR-NK cell therapy market, including detailed revenue projections across key sub-segments valuable to established players and new entrants alike.
• Offers stakeholders a clear view of market drivers, restraints, opportunities, and challenges to support data-driven strategic decisions.
• Helps businesses identify and evaluate future opportunities across cell source, target antigen, indication, and end-user segments.
• Supports customer and partner identification by clarifying the needs, preferences, and behavior of key stakeholders in South Korea's cell therapy ecosystem.
• Equips new entrants with the market intelligence required to build effective go-to-market and licensing strategies.
• Facilitates more informed, effective engagement with potential partners, distributors, and investors in the region.

ADDITIONAL BENEFITS

• Complementary Excel data packs for all analytical modules in the report
• 15% free content customization
• Detailed report walkthrough session with the research team
• Free updated report if the report is 6-12 months old or older